Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 12, 2026The Journal of Infection in Developing CountriesOpen Access

Comparing COVID-19 vaccine effectiveness in Türkiye: heterologous, inactivated, and mRNA vaccines

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAlpay ArıZAZeynep AltinayDDDidem Demircan

Discussion

Loading...

Member takes

Overview

Compares vaccine effectiveness in preventing severe COVID-19 outcomes in Türkiye, suggesting implications for public health policies.

Key Points

  • This research aims to compare the effectiveness of different COVID-19 vaccines in preventing severe outcomes.
  • Data collected from 24,538 individuals aged ≥ 18 years with confirmed COVID-19 status via PCR.
  • Survival distribution analysis conducted for six vaccine types.
  • Focused on vaccine effectiveness differences between those younger and older than 65 years.
  • Two-dose mRNA vaccines demonstrated the most protective and durable effectiveness.
  • Inactivated vaccines showed significant reductions in severe outcomes for individuals aged > 65 years compared to unvaccinated individuals.
  • Heterologous and homologous vaccines contributed to timely protection against severe COVID-19 outcomes.

Cite This Study

Arı et al. (2026) studied this question.

synapsesocial.com/papers/6a2ba1438101cf8926f00ce2https://doi.org/10.3855/jidc.21743
View Full Paper
Ask AI
Bookmark
Share